Compare Adaptive Biotechnologies Corp (ADPT) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs HSBC Holdings plc — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while HSBC Holdings plc trades at $95.95 (market cap $329.01B). The key difference: HSBC Holdings plc is far larger — about 98.8× Adaptive Biotechnologies Corp's market cap, and HSBC Holdings plc pays a 3.85% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HSBC | |
|---|---|---|
Market Cap | $3.33B | $329.01B |
Sector | Health | Technology |
52-Week High | $22.37 | $98.74 |
52-Week Low | $10.24 | $61.30 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HSBC trades at $98.74, up 2.03% with bullish technical indicators and strong earnings momentum. The stock shows consistent earnings beats with Q1 2026 EPS of $2.20 exceeding expectations. Recent developments include strategic reviews of non-core businesses and AI partnerships with Google Cloud. Valuation metrics include a P/E of 16.32 and P/B of 1.72, while maintaining a 30.81% net income margin.
HSBC presents a balanced investment case with solid fundamentals and strategic repositioning offset by regulatory risks and market volatility. The bank's focus on core markets and AI integration supports growth potential, though recent regulatory penalties and business exits warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
